# US 4,391,755 A · Steroid monohydrates, formulations containing same and method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,391,755 A
- Document ID: US4391755A
- Status: Granted
- Kind: A
- Application number: 06/340,127
- Filed: 1982-01-18
- Granted: 1983-07-05
- Earliest claimed: 1982-01-18
- Assignees: E. R. Squibb & Sons, Inc.
- Inventors: Yu-Chang J. Wang; Dursch Friedrich; Richard L. O'Laughlin; Thaddeus Prusik
- Web page: https://patentgrep.com/patent/US4391755A

## CPC

- C07J 53/002: {Carbocyclic rings fused}
- A61P 17/00: Drugs for dermatological disorders
- C07J: STEROIDS (seco-steroids C07C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A monohydrate of a steroid having the structure ##STR1## and the 1,2-dehydro derivatives thereof, is provided which monohydrate is in the form of a particulate material having a stable average particle size of less than about 20 microns. Cream and lotion formulations containing the steroid monohydrate and a method for forming the monohydrate are also provided.

## Claims

### Claim 1

A method for forming the monohydrate of a steroid, said monohydrate having an average particle size of less than about 20 microns, said steroid having the structure ##STR8## wherein R.sub.1 is chlorine, fluorine or hydroxy and R'.sub.1 is hydrogen or R.sub.1 and R'.sub.1 together are .dbd.O; R.sub.2 is hydrogen or halogen; R.sub.3 is hydrogen, methyl or fluorine; R.sub.4 is hydrogen, hydroxy, ##STR9## or halogen; and R.sub.5 and R.sub.6 are the same or different and are hydrogen, alkyl, alkylthio, alkoxy, carboalkoxy, formyl, ##STR10## hydroxy, halogen, phenyl or cyano, with the proviso that when R.sub.5 and R.sub.6 are different, one of R.sub.5 and R.sub.6 is hydrogen, which method includes the steps of micronizing the steroid in anhydrous form, introducing the micronized anhydrous steroid into water to hydrate the steroid to form the corresponding monohydrate and cause crystal growth, reducing the average particle size of the crystals of hydrated steroid suspended in water to below about 25 microns to form particles of steroid monohydrate having a relatively stable crystal size.

### Claim 2 (depends on 1)

The method as defined in claim 1 wherein the average particle size of the crystals of hydrated steroid is in the range of from about 40 to 90 microns and is reduced to an average particle size of less than about 20 microns.

### Claim 3 (depends on 1)

The method as defined in claim 1 wherein crystals of hydrated steroid are reduced to an average particle size of less than about 10 microns.

### Claim 4 (depends on 3)

The method as defined in claim 3 wherein crystals of hydrated steroid are reduced to an average particle size of less than about 5 microns.

### Claim 5 (depends on 1)

The method as defined in claim 1 wherein the anhydrous steroid is 21-(acetyloxy)-9-fluoro-1',2',3',4'-tetrahydro-11.beta.-hydroxypregna-1,4- dieno[16.alpha.,17-b]naphthalene-3,20-dione.

### Claim 6 (depends on 1)

The method as defined in claim 1 wherein the anhydrous steroid is (11.beta.,16.beta.)-9-fluoro-1',2',3',4'-tetrahydro-11,21-dihydroxypregna- 1,4-dieno-[16,17-b]naphthalene-3,20-dione.

### Claim 7 (depends on 1)

The method as defined in claim 1 wherein the micronized anhydrous steroid is allowed to remain in the water for a period of from about 0.1 to about 4 hours to allow for formation of a monohydrate and crystal growth.

### Claim 8 (depends on 1)

The method as defined in claim 1 wherein the water and micronized anhydrous steroid form a suspension containing from about 5 to about 20% steroid.

### Claim 9 (depends on 1)

The method as defined in claim 1 wherein the steroid in anhydrous form is micronized to an average particle size of below about 5 microns.

### Claim 10

A method for forming the monohydrate of a steroid, said monohydrate having an average particle size of less than 20 microns, said steroid having the structure ##STR11## wherein R.sub.1 is chlorine, fluorine or hydroxy and R'.sub.1 is hydrogen or R.sub.1 and R'.sub.1 together are .dbd.O, R.sub.2 is hydrogen or halogen; R.sub.3 is hydrogen, methyl or fluorine; R.sub.4 is hydrogen, hydroxy, ##STR12## or halogen; and R.sub.5 and R.sub.6 are the same or different and are hydrogen, alkyl, alkylthio, alkoxy, carboalkoxy, formyl, ##STR13## hydroxy, halogen, phenyl or cyano, with the proviso that when R.sub.5 and R.sub.6 are different, one of R.sub.5 and R.sub.6 is hydrogen, which method includes the steps of micronizing the steroid in anhydrous form and subjecting the micronized anhydrous steroid to a relative humidity of higher than 40% for a period of at least about 4 hours to form a monohydrate of the steroid while controlling and limiting crystal size of the steroid monohydrate.

### Claim 11 (depends on 10)

The method as defined in claim 10 wherein the anhydrous steroid is micronized to an average particle size of 10 microns or less.

### Claim 12 (depends on 10)

The method as defined in claim 10 wherein the steroid monohydrate has a stable average particle size of 5 microns or less.

### Claim 13 (depends on 10)

The method as defined in claim 10 wherein the micronized anhydrous steroid is in the form of a thin layer as it is subjected to the high relative humidity.

### Claim 14 (depends on 11)

The method as defined in claim 11 wherein the micronized anhydrous steroid is subjected to the high relative humidity for a minimal period of about one day.
